Brief: GBS Inc. Announces Institutional Review Board Approval To Initiate Clinical Trial At Sutter Health Mills-Peninsula Medical Center
31/03/2022 21:55
March 31 (Reuters) - Gbs Inc GBS.O :
* GBS INC. ANNOUNCES INSTITUTIONAL REVIEW BOARD APPROVAL TO
INITIATE CLINICAL TRIAL AT SUTTER HEALTH MILLS-PENINSULA MEDICAL
CENTER
* GBS INC - TRIAL IS EXPECTED TO ENROLL APPROXIMATELY 40
ADULT
SUBJECTS DIAGNOSED WITH TYPE 2 DIABETES
Source text for Eikon: ID:nGNX6ttNkT
Further company coverage: GBS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intelligent Bio Solutions
See all newsBrief: Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth Of 38% Year-Over-Year, Driven By Reader Installed Base And High-Margin Cartridge Growth
Brief: Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance And Planned US Market Entry
Intelligent Bio Solutions Q3 revenue rises 46%, gross margin tops 50%
Intelligent Bio Solutions rise after clearing security tests ahead of FDA filing
Brief: Intelligent Bio Solutions Completes Clinical Cut-Off Study